Silexion Therapeutics Sets 1-for-24 Reverse Stock Split Approval

Silexion Therapeutics Corp (Nasdaq: SLXN) has won shareholder approval for a reverse stock split at a 1-for-24 ratio, the company said in an 8-K filed Monday, Oct. 26.

The vote took place at an extraordinary general meeting first held Oct. 19. That meeting was adjourned for lack of a quorum and reconvened Oct. 26. At the reconvened meeting, holders of 2,697,489 ordinary shares, about 18.6% of issued and outstanding shares, were present in person or by proxy. Under the company's articles, the shareholders present then formed a quorum after a half-hour wait.

Reverse split approved

The reverse split proposal passed with 2,630,320 votes in favor, or 97.7% of votes cast, and 61,787 against. The proposal allowed the board to choose any ratio from 1-for-15 to 1-for-25, and the board set the ratio at 1-for-24. All issued and outstanding and authorized but unissued ordinary shares, with par value of $0.135, would be consolidated into a smaller number of ordinary shares with a par value of $3.24 each.

Larger authorized share capital

Shareholders also approved an increase of 500,000,000 ordinary shares in authorized share capital, with 95.4% of votes cast in favor. Authorized shares rise from 15,900,000 to 515,900,000, and authorized capital rises from US$2,146,500 to US$69,646,500. The amendment to the memorandum of association was filed with the Cayman Islands Registrar of Companies on Oct. 26 and took effect that day.

For the last fiscal year ended Dec. 31, 2025, the company reported a net loss of $11.9 million. As of June 30, 2026, it held $2.2 million in cash and equivalents.